Advertisement

The Economics of the Hematopoietic Growth Factors

  • Adi Eldar-Lissai
  • Gary H. Lyman
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 157)

Abstract

The last two decades have seen a dramatic increase in overall healthcare costs. Cancer treatment cost in the United States has increased by about 75% between 1995 and 2008, accounting for $93.2 billion in direct medical costs [1, 2]. Spending on cancer drugs has increased faster than spending on other areas of treatment (such as hospitalization), due to both increases in prices and in the rates of use. Of particular concern is that the magnitude of increase in prices exceeds the magnitude of their improvement in treatment efficacy [3].

Keywords

Economics Hematopoietic Growth Factors 

References

  1. 1.
    National Cancer Institute. Cancer Trend Progress Report-2007 Update. Available from: http://progressreport.cancer.gov/doc_detail.asp?pid=1&did=2007&chid=75&coid=726&mid=. Accessed 12 Jul 2009.
  2. 2.
    American Cancer Society. Cancer facts and figures 2009. Available from: http://www.cancer.org/downloads/STT/500809web.pdf. Accessed 12 Jul 2009.
  3. 3.
    Bach PB. Limits on Medicare’s ability to control rising spending on cancer drugs. N Engl J Med. 2009;360(6):626–33.CrossRefPubMedGoogle Scholar
  4. 4.
    Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol. 2004;22(17):3524–30.CrossRefPubMedGoogle Scholar
  5. 5.
    Greenberg D, Earle C, Fang C-H, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst. 2010;102(2):82–8.Google Scholar
  6. 6.
    Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press; 1996.Google Scholar
  7. 7.
    Drummond MF, Sculpher MJ, Torrance GW, O’brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. New York, NY: Oxford Medical Publications; 2005.Google Scholar
  8. 8.
    Berger ML, Bingefors K, Hedblom EC, Pashos CL, Torrance GW. Health care cost, quality, and outcomes, ISPOR book of terms. New Jersey: International Society for Pharmacoeconomics and Outcomes Research; 2003.Google Scholar
  9. 9.
    Lyman GH, Kuderer NM. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol. 2004;50(2):129–46.CrossRefPubMedGoogle Scholar
  10. 10.
    Stone PW, Chapman RC, Sandberg EA, Liljas B, Neumann PJ. Measuring costs in cost-utility analyses: variations in the literature. Int J Technol Assess Health Care. 2000;6(1):111–24.CrossRefGoogle Scholar
  11. 11.
    Greenberg D, Winkelmayer WC, Rosen AB, Neumann PJ, Palmer JA. Prevailing judgments about society’s willingness to pay for a QALY: do they vary by country? Have they changed over time? Philadelphia, PA: International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 2006.Google Scholar
  12. 12.
    Neumann PJ. Using cost-effectiveness analysis to improve health care: opportunities and barriers. New York, NYFord University Press; 2005.Google Scholar
  13. 13.
    Maher DW, Lieschke GJ, Green M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia: a double-blind, placebo-controlled trial. Ann Intern Med. 1994;121:492–501.PubMedGoogle Scholar
  14. 14.
    Vogel CL, Wojtukiewicz ZM, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol. 2005;23(6):1178–84.CrossRefPubMedGoogle Scholar
  15. 15.
    Crawford J, Ozer H, Stoller R, Johanson D, Lyman GH, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med. 1991;325:164–70.CrossRefPubMedGoogle Scholar
  16. 16.
    Clark OAC, Lyman GH, Castro AA, Clark LGO, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23(18):4198–214.CrossRefPubMedGoogle Scholar
  17. 17.
    Centers for Medicare and Medicaid. Medicare Part B Drug Average Sales Price 2009 ASP Drug Pricing Files. Available from: http://www.cms.hhs.gov/apps/ama/license.asp?file=/McrPartBDrugAvgSalesPrice/downloads/July_2009_ASP_Pricing_File.zip. Accessed 18 Jul 2009.
  18. 18.
    Caggiano V, Weiss RV, Richert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer. 2005;103(9):1916–24.CrossRefPubMedGoogle Scholar
  19. 19.
    Kuderer N, Dale D, Crawford J, Cosler L, Lyman G. The morbidity, mortality and cost of febrile neutropenia in cancer patients. Cancer. 2006;106(10):2258–66.CrossRefPubMedGoogle Scholar
  20. 20.
    Cosler LE, Eldar-Lissai A, Culakova E, et al. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective. PharmacoEconomics. 2007;25(4):343–51.CrossRefPubMedGoogle Scholar
  21. 21.
    Eldar-Lissai A, Cosler LE, Culakova E, Lyman GH. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health. 2008;11(2):172–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Courtney DM, Aldeen AZ, Gorman SM, et al. Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care. Oncologist. 2007;12(8):1019–26.CrossRefPubMedGoogle Scholar
  23. 23.
    Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG. Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother. 2006;40(3):402–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Ip EJ, Lee-Ma A, Troxell LS, Chan J. Low-dose filgrastim in patients with breast cancer treated with docetaxel, doxorubicin, and cyclophosphamide. Am J Health Syst Pharm. 2008;65(16):1552–55.CrossRefPubMedGoogle Scholar
  25. 25.
    Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Observational MJ. Study of the prevalence of febrile neutropenia in patients who receive filgrastim or pegfilgrastim associated with 3–4 weeks chemotherapy regimens in community oncology practices. J Manag Care Pharm. 2007;13(4):337–48.PubMedGoogle Scholar
  26. 26.
    Weycker D, Malin J, Kim J, et al. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther. 2009;31(5):1069–81.CrossRefPubMedGoogle Scholar
  27. 27.
    Talcott JA, Finberg R, Mayer RJ, The Medical GL. Course of cancer patients with fever and neutropenia: clinical identification of a low-risk subgroup at presentation. Arch Intern Med. 1988;148(12):2561–68.CrossRefPubMedGoogle Scholar
  28. 28.
    Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038–51.PubMedGoogle Scholar
  29. 29.
    Uys A, Rapoport BL, Anderson R. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer. 2004;8:555–60.Google Scholar
  30. 30.
    Carstensen M, Benn Sørensen J. Outpatient management of febrile neutropenia: time to revise the present treatment strategy. J Support Oncol. 2008;6(5):199–208.PubMedGoogle Scholar
  31. 31.
    Elting LS, Lu C, Escalante CP, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol. 2008;26(4):606–11.CrossRefPubMedGoogle Scholar
  32. 32.
    Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, Lyman GH. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy. Value Health. 2005;8(1):47–52.CrossRefPubMedGoogle Scholar
  33. 33.
    Cosler LE, Calhoun EA, Agboola O, Lyman GH. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy. 2004;24(4):488–94.CrossRefPubMedGoogle Scholar
  34. 34.
    Fortner B, Tauer K, Zhu L, et al. Medical visits for chemotherapy and chemotherapy-induced neutropenia: a survey of the impact on patient time and activities. BMC Cancer. 2004;4(1):22.CrossRefPubMedGoogle Scholar
  35. 35.
    Fortner BV, Okon TA, Zhu L, et al. Costs of human resources in delivering cancer chemotherapy and managing chemotherapy-induced neutropenia in community practice. Commun Oncol. 2004;1:23–8.Google Scholar
  36. 36.
    Song X, Fowler R, Ruiz K, Hurley D, Barron RL. Impact of neutropenic complications on short-term disability in patients with cancer receiving chemotherapy. J Med Econ. 2009;12(2):1–10.Google Scholar
  37. 37.
    Heil G, Hoelzer D, Sanz MA, et al. Long-term survival data from a phase 3 study of filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia. Leukemia. 2006;20(3):404–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Sung L, Nathan PC, Alibhai SMH, Tomlinson GA, Beyene J. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med. 2007;147(6):400–11.PubMedGoogle Scholar
  39. 39.
    Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158–67.CrossRefPubMedGoogle Scholar
  40. 40.
    Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med. 2002;112(5):406–11.CrossRefPubMedGoogle Scholar
  41. 41.
    Budman D, Berry D, Cirrincione C, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J. Natl. Cancer Inst. 1998;90(16):1205–11.CrossRefPubMedGoogle Scholar
  42. 42.
    Kwak L, Halpern J, Olshen R, Horning S. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990;8(6):963–77.PubMedGoogle Scholar
  43. 43.
    Ellis GK, Livingston RB, Gralow JR, Green SJ, Thompson T. Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J Clin Oncol. 2002;20(17):3637–43.CrossRefPubMedGoogle Scholar
  44. 44.
    Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British medical research council multicenter randomized trial. J Clin Oncol. 2000;18(2):395–404.PubMedGoogle Scholar
  45. 45.
    Lyman GH, Dale D, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21(24):4524–31.CrossRefPubMedGoogle Scholar
  46. 46.
    Crawford J, Green M, McGuire B, Combined SS. Analysis of average relative dose intensity in the chemotherapy of solid tumors with pegfilgrastim or filgrastim support. Support Cancer Ther. 2005;2(4):229–33.CrossRefPubMedGoogle Scholar
  47. 47.
    Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol. 2003;14(1):29–35.CrossRefPubMedGoogle Scholar
  48. 48.
    Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol. 2002;20(3):727–31.CrossRefPubMedGoogle Scholar
  49. 49.
    Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2003;21(16):3041–50.CrossRefPubMedGoogle Scholar
  50. 50.
    Brown RE, Hutton J, Burrell A. Cost effective of treatment options in advanced breast cancer in the UK. PharmacoEconomics. 2001;19(11):1091–102.CrossRefPubMedGoogle Scholar
  51. 51.
    Launois R, Reboul-Marty J, Henry B, Bonneterre J. A cost-utility of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. PharmacoEconomics. 1996;11(5):492–97.Google Scholar
  52. 52.
    Smith TJ, Khatcheressian J, Lyman GH, et al. Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–205.CrossRefPubMedGoogle Scholar
  53. 53.
    Basu SK, Fernandez ID, Fisher SG, Asselin BL, Lyman GH. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol. 2005;23(31):7958–66.CrossRefPubMedGoogle Scholar
  54. 54.
    Wittman B, Horan J, Lyman GH. Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials. Cancer Treat Rev. 2006;32(4):289–303.CrossRefPubMedGoogle Scholar
  55. 55.
    Chrischilles E, Delgado DJ, Stolshek BS, Lawless G, Fridman M, Carter WB. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in chop-treated non-Hodgkin’s lymphoma. Cancer Control. 2002;9:203–11.PubMedGoogle Scholar
  56. 56.
    Balducci L. Supportive care of elderly patients with cancer. Support Care Ther. 2005;2(4):225–8.CrossRefGoogle Scholar
  57. 57.
    Lyman G, Lyman C, Sanderson R, Balducci L. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst. 1993;85:488–93.CrossRefPubMedGoogle Scholar
  58. 58.
    Lyman GH, Balducci L. A cost analysis of hematopoietic colony-stimulating factors. Oncology. 1995;9:85–91.PubMedGoogle Scholar
  59. 59.
    Esser M, Brunner H. Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia. ADIS International Limited, 2003.Google Scholar
  60. 60.
    Lyman GH, Lalla A, Barron RL, Dubois RW. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin Ther. 2009;31(5):1092–104.CrossRefPubMedGoogle Scholar
  61. 61.
    Lyman GH, Lalla A, Barron RL, Dubois RW. Cost-effective of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin’s lymphoma receiving CHOP-21 in United States. Curr Med Res Opin. 2009;25(2):401–11.CrossRefPubMedGoogle Scholar
  62. 62.
    Ramsey SD, Liu Z, Rob B, et al. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. Value Health. 2009;12(2):217–25.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.AssociateAnalysis Group, Inc.BostonUSA
  2. 2.Duke University and the Duke Comprehensive Cancer CenterDurhamUSA

Personalised recommendations